Mar 20, 2018
Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand clinical investigation and what is its future potential?
The use of systemic chemotherapy for the treatment of haematological malignancies and solid tumours relies on three established pillars; cytotoxic chemotherapy, targeted treatments and immunotherapy. In combining the use of these pillars, large steps forward have been taken in oncology.
The original article this episode is based on was written by Dr Thomas Mehrling.
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: